For: | Reshetnyak VI. Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J Gastroenterol 2006; 12(45): 7250-7262 [PMID: 17143938 DOI: 10.3748/wjg.v12.i45.7250] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v12/i45/7250.htm |
Number | Citing Articles |
1 |
Vasiliy I. Reshetnyak, Igor V. Maev. Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. Biomedicines 2022; 10(12): 3046 doi: 10.3390/biomedicines10123046
|
2 |
Nobuyuki Tamaki, Etsuro Hatano, Kojiro Taura, Masaharu Tada, Yuzo Kodama, Takashi Nitta, Keiko Iwaisako, Satoru Seo, Akio Nakajima, Iwao Ikai, Shinji Uemoto. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008; 294(2): G498 doi: 10.1152/ajpgi.00482.2007
|
3 |
Filippo Gabrielli, Eleonora Crepaldi, Alessia Cavicchioli, Marco Rivi, Arianna Carmen Costanzo, Carmela Cursaro, Pietro Andreone. Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments. Biomolecules 2024; 14(10): 1227 doi: 10.3390/biom14101227
|
4 |
V. I. Reshetnyak, I. V. Maev. Dyslipidemia and its features in primary biliary cholangitis. Health care of Tajikistan 2023; (1): 119 doi: 10.52888/0514-2515-2023-356-1-119-130
|
5 |
Klaas Poelstra, Jai Prakash, Leonie Beljaars. Drug targeting to the diseased liver. Journal of Controlled Release 2012; 161(2): 188 doi: 10.1016/j.jconrel.2012.02.011
|
6 |
Vasiliy I. Reshetnyak, Igor V. Maev, Tatiana M. Reshetnyak, Sergei V. Zhuravel, Vladimir M. Pisarev. Liver Disease and Hemostasis (Review) Part 2. Cholestatic Liver Disease and Hemostasis. General Reanimatology 2019; 15(6): 80 doi: 10.15360/1813-9779-2019-6-80-93
|
7 |
Benedikte Richter, Anne Roslind, Ulrik Hesse, Jørgen Nordling, Julia Sidenius Johansen, Thomas Horn, Alastair Bierre Hansen. YKL‐40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010; 57(3): 371 doi: 10.1111/j.1365-2559.2010.03640.x
|
8 |
I. Grattagliano, P.J. Oliveira, L. Vergani, P. Portincasa. Liver Pathophysiology. 2017; : 225 doi: 10.1016/B978-0-12-804274-8.00017-5
|
9 |
Saeam Shin, In Ho Moh, Young Sik Woo, Sung Won Jung, Jin Bae Kim, Ji Won Park, Ki Tae Suk, Hyoung Su Kim, Mineui Hong, Sang Hoon Park, Myung Seok Lee. Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis. World Journal of Gastroenterology 2017; 23(39): 7191-7197 doi: 10.3748/wjg.v23.i39.7191
|
10 |
Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev. Pathophysiology of biochemical signs of primary biliary cholangitis. Exploration of Digestive Diseases 2023; : 149 doi: 10.37349/edd.2023.00024
|
11 |
Vasiliy Ivanovich Reshetnyak. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World Journal of Gastroenterology 2015; 21(25): 7683-7708 doi: 10.3748/wjg.v21.i25.7683
|
12 |
Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev. Mechanism for development of malnutrition in primary biliary cholangitis. World Journal of Meta-Analysis 2022; 10(3): 81-98 doi: 10.13105/wjma.v10.i3.81
|
13 |
Paul‐Henry Koop, Constanze Schwenzer, Jan Clusmann, Mara S. Vell, Julius Jaeger, Wenfang Gui, Christian Trautwein, Alexander Koch, Tony Bruns, Carolin V. Schneider, Kai Markus Schneider. Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study. Liver International 2024; 44(8): 2038 doi: 10.1111/liv.15945
|
14 |
Hiroto Tsuboi, Hiromasa Ohira, Hiromitsu Asashima, Sayaka Tsuzuki, Mana Iizuka, Naomi Matsuo, Yuya Kondo, Isao Matsumoto, Takayuki Sumida. Anti‐M3 muscarinic acetylcholine receptor antibodies in patients with primary biliary cirrhosis. Hepatology Research 2014; 44(14) doi: 10.1111/hepr.12346
|
15 |
Neel Deferm, Tom De Vocht, Bing Qi, Pieter Van Brantegem, Eva Gijbels, Mathieu Vinken, Peter de Witte, Thomas Bouillon, Pieter Annaert. Current insights in the complexities underlying drug-induced cholestasis. Critical Reviews in Toxicology 2019; 49(6): 520 doi: 10.1080/10408444.2019.1635081
|